StemlineTherapeutics (STML) Stock Rating Upgraded by Zacks Investment Research

StemlineTherapeutics (NASDAQ:STML) was upgraded by Zacks Investment Research from a “sell” rating to a “hold” rating in a report issued on Tuesday.

According to Zacks, “Stemline Therapeutics, Inc. is a biopharmaceutical company developing oncology therapeutics that target cancer stem cells and tumor bulk. The company is developing SL-401, a biologic-drug conjugate, for relapsed or refractory acute myeloid leukemia; and SL-701, a synthetic peptide vaccine, for pediatric and adult high-grade gliomas. Stemline Therapeutics, Inc. is based in New York. “

A number of other research analysts have also recently issued reports on STML. HC Wainwright set a $38.00 price objective on shares of StemlineTherapeutics and gave the company a “buy” rating in a report on Thursday, May 10th. ValuEngine cut shares of StemlineTherapeutics from a “buy” rating to a “hold” rating in a report on Monday, May 14th. BidaskClub upgraded shares of StemlineTherapeutics from a “buy” rating to a “strong-buy” rating in a report on Tuesday, May 8th. Finally, Cowen reiterated a “buy” rating on shares of StemlineTherapeutics in a report on Thursday, May 10th. Two research analysts have rated the stock with a hold rating, three have issued a buy rating and one has issued a strong buy rating to the company. The company has a consensus rating of “Buy” and an average target price of $27.00.

Shares of NASDAQ STML opened at $19.40 on Tuesday. The stock has a market cap of $588.83 million, a PE ratio of -6.60 and a beta of 0.01. StemlineTherapeutics has a 1 year low of $7.30 and a 1 year high of $20.20.

StemlineTherapeutics (NASDAQ:STML) last issued its quarterly earnings data on Friday, March 16th. The biopharmaceutical company reported ($0.93) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.67) by ($0.26). StemlineTherapeutics had a negative net margin of 4,689.63% and a negative return on equity of 101.93%. sell-side analysts anticipate that StemlineTherapeutics will post -2.72 EPS for the current fiscal year.

In related news, CEO Ivan Bergstein sold 24,183 shares of the business’s stock in a transaction dated Tuesday, February 27th. The shares were sold at an average price of $17.42, for a total transaction of $421,267.86. The transaction was disclosed in a legal filing with the SEC, which can be accessed through the SEC website. Also, COO Kenneth Hoberman sold 29,987 shares of the business’s stock in a transaction dated Tuesday, March 13th. The stock was sold at an average price of $17.14, for a total transaction of $513,977.18. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 132,457 shares of company stock worth $2,286,115. 15.70% of the stock is owned by corporate insiders.

A number of institutional investors have recently added to or reduced their stakes in STML. Consonance Capital Management LP boosted its holdings in StemlineTherapeutics by 2,216.9% during the fourth quarter. Consonance Capital Management LP now owns 2,349,792 shares of the biopharmaceutical company’s stock worth $36,657,000 after purchasing an additional 2,248,372 shares during the last quarter. Citadel Advisors LLC purchased a new position in StemlineTherapeutics during the first quarter worth about $8,948,000. venBio Select Advisor LLC purchased a new position in StemlineTherapeutics during the first quarter worth about $8,022,000. Nexthera Capital LP purchased a new position in StemlineTherapeutics during the first quarter worth about $8,011,000. Finally, Lyon Street Capital LLC boosted its holdings in StemlineTherapeutics by 49.7% during the first quarter. Lyon Street Capital LLC now owns 1,241,293 shares of the biopharmaceutical company’s stock worth $18,992,000 after purchasing an additional 412,203 shares during the last quarter. Institutional investors and hedge funds own 64.40% of the company’s stock.

StemlineTherapeutics Company Profile

Stemline Therapeutics, Inc, a clinical stage biopharmaceutical company, focuses on the discovery, acquisition, development, and commercialization of proprietary oncology therapeutics in the United States and internationally. The company develops SL-401, a targeted therapy directed to the interleukin-3 receptor (IL-3R), which has completed Phase II clinical trial for patients with blastic plasmacytoid dendritic cell neoplasm; is in Phase I/II clinical trials for patients with myeloproliferative neoplasms, chronic myelomonocytic leukemia, myelofibrosis, and acute myeloid leukemia; and is in Phase I clinical trial in combination with other agents for patients with relapsed/refractory multiple myeloma.

Get a free copy of the Zacks research report on StemlineTherapeutics (STML)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for StemlineTherapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for StemlineTherapeutics and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply